Aswin Nagarajan*, Arun Sakthivelu, Narendran Santhanaraman, Ramya Ravichandar
Nagarajan et al. J Clin Transl Res 2021; 7(2):15
Published online: April 16, 2021
Abstract
Background: Nimotuzumab is a monoclonal antibody against epidermal growth factor receptor which can be combined with chemotherapy and radiotherapy for the treatment of locally advanced unresectable squamous cell carcinoma of head and neck region and its role has already been established in India.
Aim: The aim of this case report is to show the role of nimotuzumab in carcinoma hypopharynx.
Methods: We report a patient with stage III carcinoma of hypopharynx, who received radiotherapy along with weekly nimotuzumab owing to his comorbidities. The patient had tolerated the treatment very well without any major side effects.
Results: The patient is on regular follow-up with a complete response (CR) of the disease and with the disease free interval (DFI) of 7 months.
Conclusions: Nimotuzumab along with radiotherapy can be safely given in the patients with carcinoma hypopharynx, who are ineligible for chemotherapy.
Relevance for patients: Nimotuzumab can be added with radiotherapy to the patients with head and neck malignancies who are ineligible for chemotherapy in order to improve the clinical outcome with minimal toxicity.
DOI: http://dx.doi.org/10.18053/jctres.07.202102.015
Author affilation
1. Department of Radiation Oncology, Cancer institute , Adyar, Chennai, Tamil Nadu, India
2. Assistant Professor, Department of Pharmacology, Sree Balaji Medical College and Hospital, Chennai, India
*Corresponding author
Aswin Nagarajan
Department of Radiation Oncology, Cancer institute, 38, Sardar Patel road,
Adyar, Chennai – 600020, Tamil Nadu, India
Tel: 9444803075
Email: ashwinnagu@rediffmail.com
Handling editor:
Michal Heger
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China
Downloads
Full text PDF
Review process file (213.5 KB)
